BALAXI PHARMACEUTICALS LIMITED — Results, 30-05-2025: Integrated Filing- Financial

Balaxi Pharmaceuticals has announced a board meeting on May 30, 2025, approving consolidated financial results for FY25.

1) Revenue Performance: Consolidated revenue from operations declined 16% YoY to Rs. 202.56 Cr, primarily due to lower volumes in its specialized wholesale segment.

2) Profitability and EPS: Net profit surged to Rs. 25.07 Cr from a loss of Rs. 2.39 Cr last year. EPS improved to Rs. 2.27, supported by enhanced operational efficiency and reduced exceptional costs.

3) Operational Costs: Total expenses dropped to Rs. 198.34 Cr from Rs. 260.18 Cr, driven by lower employee benefits and admin expenses, despite a slight rise in raw material costs. Finance costs edged up modestly but overall cost control improved margins.

4) Key Metrics: Profit before tax jumped to Rs. 30.31 Cr from Rs. 2.87 Cr, reflecting better operational leverage, though EBITDA details were not disclosed separately.

5) Balance Sheet / Cash Flow Health: Total assets increased to Rs. 310.34 Cr, with borrowings at Rs. 21.24 Cr. Cash reserves remain strong at Rs. 39.40 Cr. Ongoing capex for plant expansion underlines growth investment.

6) Management Commentary / Strategic Outlook: The new pharma formulation plant in Jadcherla, Hyderabad, is in final validation stages, with manufacturing license applied for, setting the stage for future product launches and capacity ramp-up.

Balaxi’s profit turnaround amid revenue pressure and progress on its manufacturing front signal encouraging momentum. Retail investors may find value in this improving operational discipline and growth-oriented capex.